Zacks Research Weighs in on STERIS’s Q3 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Analysts at Zacks Research raised their Q3 2025 EPS estimates for STERIS in a note issued to investors on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.30 per share for the quarter, up from their previous estimate of $2.29. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.07 EPS, Q1 2026 earnings at $2.25 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.92 EPS, Q1 2027 earnings at $2.47 EPS and FY2027 earnings at $10.25 EPS.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period last year, the business posted $2.03 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year.

A number of other research analysts also recently issued reports on the company. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and raised their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Stephens reiterated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. JMP Securities reissued a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $262.50.

STERIS Price Performance

NYSE:STE opened at $207.98 on Friday. The firm has a market cap of $20.53 billion, a price-to-earnings ratio of 47.48 and a beta of 0.83. STERIS has a one year low of $197.82 and a one year high of $248.24. The firm’s fifty day moving average is $217.49 and its two-hundred day moving average is $226.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th were paid a dividend of $0.57 per share. The ex-dividend date was Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.10%. STERIS’s dividend payout ratio is currently 52.05%.

Insider Transactions at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On STERIS

Hedge funds and other institutional investors have recently modified their holdings of the business. Franklin Resources Inc. grew its stake in STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after acquiring an additional 529,308 shares in the last quarter. Tidal Investments LLC grew its position in shares of STERIS by 21.0% in the third quarter. Tidal Investments LLC now owns 12,650 shares of the medical equipment provider’s stock valued at $3,068,000 after purchasing an additional 2,193 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of STERIS in the third quarter valued at approximately $9,949,000. World Investment Advisors LLC acquired a new stake in shares of STERIS in the third quarter valued at approximately $5,171,000. Finally, SkyView Investment Advisors LLC lifted its position in STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after buying an additional 51 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.